Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 3, 2015, Pages 247-256

  Venza, Mario ^a   Visalli, Maria ^b   Biondo, Carmelo ^a   Lentini, Maria ^a   Catalano, Teresa ^b   Teti, Diana ^b   Venza, Isabella ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Epi drug; Histone deacetylation; Human melanoma; P14ARF; P16INK4A; Promoter methylation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DECITABINE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; HISTONE H3; HISTONE H4; LYSINE; MESSENGER RNA; AZACITIDINE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HISTONE DEACETYLASES; TUMOR SUPPRESSOR PROTEIN P14ARF;

ACETYLATION; ADULT; ARTICLE; BRESLOW THICKNESS; CANCER CLASSIFICATION; CANCER SIZE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; CUTANEOUS MELANOMA; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; FEMALE; GENE INACTIVATION; GENE SILENCING; GENETIC REGULATION; GENETIC TRAIT; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; UVEA MELANOMA; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CELL LINE, TUMOR; DRUG EFFECTS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; MELANOMA; PATHOLOGY; PROMOTER REGIONS, GENETIC; UVEAL NEOPLASMS;

ADULT; AZACITIDINE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASES; HUMANS; MELANOMA; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEIN P14ARF; UVEAL NEOPLASMS;

EID: 84921496342     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.12.004     Document Type: Article

References (46)

1. van den Bosch T., Kilic E., Paridaens D., de Klein A. Genetics of uveal melanoma and cutaneous melanoma: two of a kind?. Dermatol. Res. Pract. 2010, 2010:360136.
2. Caffo M., Barresi V., Caruso G., Cutugno M., La Fata G., Venza M., Alafaci C., Tomasello F. Innovative therapeutic strategies in the treatment of brain metastases. Int. J. Mol. Sci. 2013, 14:2135-2174.
3. Bataille V. Sun exposure, sunbeds and sunscreens and melanoma. What are the controversies?. Curr. Oncol. Rep. 2013, 15:526-532.
4. Kessides M.C., Wheless L., Hoffman-Bolton J., Clipp S., Alani R.M., Alberg A.J. Cigarette smoking and malignant melanoma: a case-control study. J. Am. Acad. Dermatol. 2011, 64:84-90.
5. Roszkowska A.M., De Grazia L., Visalli M., Mondello M., Teti D., Venza M., Venza I. Contact lens wearing and chronic cigarette smoking positively correlate with TGF-β1 and VEGF tear levels and impaired corneal wound healing after photorefractive keratectomy. Curr. Eye Res. 2013, 38:335-341.
6. van den Hurk K., Niessen H.E., Veeck J., van den Oord J.J., van Steensel M.A., Zur Hausen A., van Engeland M., Winnepenninckx V.J. Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune. Biochim. Biophys. Acta 2012, 1826:89-102.
7. Merhavi E., Cohen Y., Avraham B.C., Frenkel S., Chowers I., Pe'er J., Goldenberg-Cohen N. Promoter methylation status of multiple genes in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2007, 48:4403-4406.
8. Tannapfel A., Busse C., Weinans L., Benicke M., Katalinic A., Geissler F., Hauss J., Wittekind C. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Oncogene 2001, 20:7104-7109.
9. Burri N., Shaw P., Bouzourene H., Sordat I., Sordat B., Gillet M., Schorderet D., Bosman F.T., Chaubert P. Methylation silencing and mutations of the p14ARF and 16INK4a genes in colon cancer. Lab. Investig. 2001, 81:217-229.
10. Shahnavaz S.A., Bradkey G., Regezi J.A., Thakker N., Gao L., Hogg D., Jordan R.C. Patterns of CDKN2A gene loss in sequential oral epithelial dysplasias and carcinomas. Cancer Res. 2001, 61:2371-2375.
11. Hashemi J., Lindström M.S., Asker C., Platz A., Hansson J., Wiman K.G. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett. 2002, 180:211-221.
12. Freedberg D.E., Rigas S.H., Russak J., Gai W., Kaplow M., Osman I., Turner F., Randerson-Moor J.A., Houghton A., Busam K., Timothy Bishop D., Bastian B.C., Newton-Bishop J.A., Polsky D. Frequent p16-independent inactivation of p14ARF in human melanoma. J. Natl. Cancer Inst. 2008, 100:784-795.
13. Gonzalgo M.L., Bender C.M., You E.H., Glendening J.M., Flores J.F., Walker G.J., Hayward N.K., Jones P.A., Fountain J.W. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors. Cancer Res. 1997, 57:5336-5347.
14. INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene 1999, 18:2527-2532.
15. Tellez C.S., Shen L., Estécio M.R., Jelinek J., Gershenwald J.E., Issa J.P. CpG island methylation profiling in human melanoma cell lines. Melanoma Res. 2009, 19:146-155.
16. Jonsson A., Tuominen R., Grafström E., Hansson J., Egyhazi S. High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. J. Investig. Dermatol. 2010, 130:2809-2817.
17. van der Velden P.A., Metzelaar-Blok J.A., Bergman W., Monique H., Hurks H., Frants R.R., Gruis N.A., Jager M.J. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma. Cancer Res. 2001, 61:5303-5306.
18. Edmunds S.C., Kelsell D.P., Hungerford J.L., Cree I.A. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2002, 43:2845-2851.
19. Zeschnigk M., Tschentscher F., Lich C., Brandt B., Horsthemke B., Lohmann D.R. Methylation analysis of several tumour suppressor genes shows a low frequency of methylation of CDKN2A and RARB in uveal melanomas. Comp. Funct. Genom. 2003, 4:329-336.
20. Moulin A.P., Clément G., Bosman F.T., Zografos L., Benhattar J. Methylation of CpG island promoters in uveal melanoma. Br. J. Ophthalmol. 2008, 92:281-285.
21. Sigalotti L., Covre A., Fratta E., Parisi G., Colizzi F., Rizzo A., Danielli R., Nicolay H.J., Coral S., Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J. Transl. Med. 2010, 8:56.
22. Landreville S., Agapova O.A., Matatall K.A., Kneass Z.T., Onken M.D., Lee R.S., Bowcock A.M., Harbour J.W. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin. Cancer Res. 2012, 18:408-416.
23. Venza I., Visalli M., Oteri R., Cucinotta M., Teti D., Venza M. Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells. Pigment Cell Melanoma Res. 2013, 26:193-204.
24. Ou Y.H., Chung P.H., Hsu F.F., Sun T.P., Chang W.Y., Shieh S.Y. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J. 2007, 26:3968-3980.
25. Hara E., Smith R., Parry D., Tahara H., Stone S., Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 1996, 16:859-867.
26. Venza M., Visalli M., Alafaci C., Caffo M., Caruso G., Salpietro F.M., Tomasello F., Teti D. Interleukin-8 overexpression in astrocytomas is induced by prostaglandin E2 and is associated with the transcription factors CCAAT/enhancer-binding protein-β and CCAAT/enhancer-binding homologous protein. Neurosurgery 2011, 69:713-721. (discussion 721).
27. Pérot G., Chibon F., Montero A., Lagarde P., de Thé P.H., Terrier P., Guillou L., Ranchère D., Coindre J.M., Aurias A. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am. J. Pathol. 2010, 177:2080-2090.
28. INK4a methylation and p53 mutational status. Cancer Res. 2000, 60:129-133.
29. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:9821-9826.
30. Xu L., Deng X. Suppression of cancer cell migration and invasion by protein phosphatase 2A through dephosphorylation of mu- and m-calpains. J. Biol. Chem. 2006, 281:35567-35575.
31. Riker A.I., Enkemann S.A., Fodstad O., Liu S., Ren S., Morris C., Xi Y., Howell P., Metge B., Samant R.S., Shevde L.A., Li W., Eschrich S., Daud A., Ju J., Matta J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genom. 2008, 28. (1:13).
32. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet. Dev. 1999, 9:22-30.
33. Chang Z., Li Z., Wang X., Kang Y., Yuan Y., Niu J., Wang H., Chatterjee D., Fleming J.B., Li M., Abbruzzese J.L., Chiao P.J. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells. Clin. Cancer Res. 2013, 19:549-559. 10.1158/1078-0432.
34. Merbs S.L., Sidransky D. Analysis of p16 (CDKN2/MTS-1/INK4A) alterations in primary sporadic uveal melanoma. Invest. Ophthalmol. Vis. Sci. 1999, 40:779-783.
35. Lamperska K., Mackiewicz K., Kaczmarek A., Kwiatkowska E., Starzycka M., Romanowska B., Heizman J., Stachura J., Mackiewicz A. Expression of p16 in sporadic primary uveal melanoma. Acta Biochim. Pol. 2002, 49:377-385.
36. Stone S., Jiang P., Dayananth P., Tavtigian S.V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 1995, 55:2988-2994.
37. Sharpless N.E., Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003, 22:3092-3098.
38. Hearle N., Damato B.E., Humphreys J., Wixey J., Green H., Stone J., Easton D.F., Houlston R.S. Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest. Ophthalmol. Vis. Sci. 2003, 44:458-462.
39. Buecher B., Gauthier-Villars M., Desjardins L., Lumbroso-Le Rouic L., Levy C., De Pauw A., Bombled J., Tirapo C., Houdayer C., Bressac-de Paillerets B., Stoppa-Lyonnet D. Contribution of CDKN2A/P16 (INK4A), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma. Familial Cancer 2010, 9:663-667.
40. Furuta J., Umebayashi Y., Miyamoto K., Kikuchi K., Otsuka F., Sugimura T., Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci. 2004, 23:4014-4022.
41. Straume O., Smeds J., Kumar R., Hemminki K., Akslen L.A. Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase. Am. J. Pathol. 2002, 161:229-237.
42. Yuan D., Ye S., Pan Y., Bao Y., Chen H., Shao C. Long-term cadmium exposure leads to the enhancement of lymphocyte proliferation via down-regulating p16 by DNA hypermethylation. Mutat. Res. 2013, 757:125-131.
43. Straume O., Sviland L., Akslen L.A. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin. Cancer Res. 2000, 6:1845-1853.
44. Dreidax D., Gogolin S., Schroeder C., Muth D., Brueckner L.M., Hess E.M., Zapatka M., Theißen J., Fischer M., Ehemann V., Schwab M., Savelyeva L., Westermann F. Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis. Hum. Mol. Genet. 2013, 22:1735-1745.
45. Lu Y., Zhang X., Zhang J. Inhibition of breast tumor cell growth by ectopic expression of p16/INK4A via combined effects of cell cycle arrest, senescence and apoptotic induction, and angiogenesis inhibition. J. Cancer 2012, 3:333-344.
46. Fung C., Pupo G.M., Scolyer R.A., Kefford R.F., Rizos H. p16(INK) (4a) deficiency promotes DNA hyper-replication and genetic instability in melanocytes. Pigment Cell Melanoma Res. 2013, 26:236-246.